Rezdiffra (Resmetirom) and Gabapentin Interaction: Safety, Risks, and Clinical Guidance

Why This Combination Comes Up in Practice

Patients with metabolic dysfunction-associated steatohepatitis (MASH) frequently carry comorbidities that require gabapentin. The overlap is not rare. Peripheral neuropathy affects an estimated 26% of patients with metabolic syndrome according to data published in the Journal of Clinical Endocrinology & Metabolism [1]. MASH patients also present with higher rates of chronic pain conditions, restless legs syndrome, and anxiety disorders for which gabapentin may be prescribed.

Resmetirom (brand name Rezdiffra) received FDA approval in March 2024, making it the first drug specifically indicated for non-cirrhotic MASH with moderate-to-advanced hepatic fibrosis (stages F2 and F3) [2]. Because the drug is new, interaction data with commonly co-prescribed agents like gabapentin remains limited to mechanistic inference and label-based analysis rather than dedicated DDI trials.

Clinicians managing both conditions in the same patient need a framework for evaluating risk. This article provides that framework by examining each drug's pharmacokinetic profile, identifying theoretical interaction points, and offering monitoring guidance based on available evidence.

Pharmacokinetic Profiles: Where the Pathways Diverge

The pharmacokinetic profiles of resmetirom and gabapentin are nearly opposite in their metabolic handling, which is the primary reason a direct interaction is unlikely.

Resmetirom undergoes extensive hepatic metabolism. The FDA label identifies CYP3A4 as the major enzyme responsible for its biotransformation, with CYP2C8 playing a secondary role [2]. The drug also interacts with organic anion transporting polypeptides (OATP1B1 and OATP1B3), which mediate its hepatic uptake. Strong CYP3A4 inhibitors increase resmetirom exposure, and the label warns against concomitant use with strong CYP3A4 inducers [2].

Gabapentin, by contrast, undergoes zero hepatic metabolism. It is not a substrate, inhibitor, or inducer of any CYP enzyme [3]. The drug is absorbed via the L-amino acid transport system in the gut, circulates with negligible protein binding (less than 3%), and is eliminated entirely by renal excretion as unchanged drug. Its half-life is 5 to 7 hours in patients with normal renal function, extending significantly in those with impaired GFR [3].

Because gabapentin does not touch the CYP system and resmetirom does not depend on renal clearance for elimination, the two drugs occupy pharmacokinetic lanes that do not intersect.

Does Resmetirom Affect Renal Function Indirectly?

This question matters because gabapentin clearance depends entirely on kidney function. Any drug that alters GFR could change gabapentin serum levels.

Resmetirom is a selective thyroid hormone receptor beta (THR-beta) agonist. THR-beta activation in the liver drives the drug's intended effects on lipid metabolism and hepatic fat reduction. THR-alpha receptors, which mediate cardiac and bone effects of thyroid hormone, are not significantly activated at therapeutic doses according to the MAESTRO-NASH trial data [4]. The phase 3 MAESTRO-NASH trial (N=966) demonstrated that resmetirom 80 mg and 100 mg achieved MASH resolution without worsening fibrosis in 25.9% and 29.9% of patients respectively at 52 weeks, compared to 9.7% for placebo [4].

Thyroid hormone excess (whether endogenous or exogenous) can increase renal blood flow and GFR. Hyperthyroid patients commonly show elevated creatinine clearance [5]. The question is whether resmetirom's selective THR-beta agonism produces a similar effect. In MAESTRO-NASH, no clinically significant changes in serum creatinine or eGFR were reported in the resmetirom arms compared to placebo through 52 weeks of treatment [4]. This suggests that at approved doses, resmetirom does not meaningfully shift renal hemodynamics.

A patient with pre-existing chronic kidney disease (CKD) deserves closer attention. Gabapentin dosing is already reduced in CKD stages 3 through 5 per the prescribing information [3]. If resmetirom were to produce even a modest change in GFR through THR-beta-mediated metabolic shifts, the effect on gabapentin levels could be amplified in a patient already on a renally adjusted dose. This remains theoretical but is worth tracking.

CNS Depression: The Pharmacodynamic Overlap That Matters

The more relevant clinical concern with this combination is not pharmacokinetic. It is pharmacodynamic.

Gabapentin carries an FDA boxed warning (added in 2019) regarding the risk of respiratory depression when combined with CNS depressants, particularly opioids [6]. Even without opioid co-administration, gabapentin alone produces somnolence in 19% to 21% of patients in clinical trials for postherpetic neuralgia and causes dizziness in 17% to 28% of patients [3].

Resmetirom's adverse event profile in MAESTRO-NASH included diarrhea (27.5% at 100 mg) and nausea (18.2% at 100 mg) as the most common effects [4]. CNS-specific adverse events were less prominent. Dizziness was reported but not at rates significantly exceeding placebo. The drug does not carry a sedation warning.

The indirect concern arises from thyroid hormone's known CNS effects. THR-beta is expressed in the brain, particularly in the hypothalamus and cortex [7]. While resmetirom was designed for liver-selective uptake through first-pass hepatic extraction and OATP-mediated transport, some systemic exposure occurs. Patients who are sensitive to CNS effects may experience fatigue or mild cognitive changes during dose titration.

When a patient takes both drugs, additive drowsiness or dizziness could impair driving or operating machinery. This risk increases in older adults (65 and older), patients on other CNS-active medications, and those with hepatic impairment that could increase resmetirom systemic exposure.

Transporter-Level Considerations: OATP and P-glycoprotein

Resmetirom is a substrate of OATP1B1 and OATP1B3 transporters, which support its hepatic uptake [2]. The FDA label notes that concomitant use with OATP1B1/1B3 inhibitors (such as cyclosporine) may increase resmetirom plasma concentrations. Resmetirom also inhibits BCRP (breast cancer resistance protein) at clinically relevant concentrations, which led the FDA to recommend monitoring when co-administered with BCRP substrates like rosuvastatin [2].

Gabapentin is not a substrate of OATP1B1, OATP1B3, BCRP, or P-glycoprotein [3]. Its absorption depends on the LAT1 (L-type amino acid transporter 1) system in the intestine, a saturable process that limits bioavailability at higher doses. Because gabapentin's absorption and elimination pathways do not involve any of the transporters that resmetirom interacts with, a transporter-mediated interaction between these two drugs is not expected.

This is an area where the pharmacology provides genuine reassurance rather than just an absence of evidence.

Thyroid Hormone Shifts and Gabapentin Tolerability

Resmetirom suppresses TSH and can lower circulating T4 and T3 levels through feedback inhibition of the hypothalamic-pituitary-thyroid axis [2]. In MAESTRO-NASH, mean TSH decreased from baseline in both the 80 mg and 100 mg groups, with some patients reaching TSH values below 0.5 mIU/L [4]. Free T4 also decreased in a subset of patients.

This matters for gabapentin tolerability for a specific reason. Hypothyroid-range thyroid function (even subclinical) is associated with peripheral neuropathy progression and altered pain thresholds [8]. If a patient is taking gabapentin for diabetic neuropathy or another pain condition, and resmetirom shifts their thyroid axis toward a functionally hypothyroid state through TSH suppression with inadequate peripheral T3 compensation, the underlying neuropathic pain could worsen. The patient might attribute increased symptoms to gabapentin failure rather than recognizing the endocrine shift.

Monitoring thyroid function every 6 to 8 weeks during resmetirom initiation, then every 3 to 6 months during maintenance, aligns with the FDA label recommendation and addresses this concern [2].

Who Needs Closer Monitoring

Not every patient on both drugs needs the same surveillance intensity. Risk stratification helps allocate clinical attention where it is most needed.

Higher-risk patients include those over 65, patients with eGFR below 60 mL/min/1.73m², anyone taking three or more CNS-active medications concurrently, and patients with a history of falls or respiratory disease. For these patients, consider checking a gabapentin trough level at baseline and 4 to 6 weeks after starting resmetirom, monitoring thyroid function at 6-week intervals during dose titration, and screening for excessive sedation at each visit using a standardized tool like the Epworth Sleepiness Scale.

Standard-risk patients (younger than 65, normal renal function, no other CNS depressants) can follow the routine monitoring schedule in the resmetirom prescribing information: liver enzymes at baseline and periodically, thyroid function tests per label guidance, and standard gabapentin follow-up as clinically indicated [2].

The American Association for the Study of Liver Diseases (AASLD) 2023 practice guidance on MASH management recommends regular hepatic and metabolic panel monitoring for all patients on MASH-directed pharmacotherapy [9]. This framework already captures most of the labs needed to track potential interactions.

Dose-Adjustment Guidance

Neither the resmetirom nor the gabapentin FDA label mandates dose adjustment when the two drugs are co-administered. No dedicated drug interaction study has been conducted for this pair.

In the absence of specific data, dose adjustments should be guided by clinical response and tolerability. If a patient reports new-onset drowsiness or worsening sedation after adding resmetirom to an existing gabapentin regimen, reducing the gabapentin dose by 25% to 33% while monitoring pain control is a reasonable first step. Resmetirom dose reduction from 100 mg to 80 mg is another option, though this may reduce efficacy for MASH fibrosis endpoints based on the dose-response relationship observed in MAESTRO-NASH [4].

For patients starting both drugs simultaneously, initiating resmetirom first and adding gabapentin 2 to 4 weeks later (or vice versa) allows attribution of adverse effects to a single agent.

What the DDI Databases Say

Major drug interaction databases (Lexicomp, Micromedex, Clinical Pharmacology) do not currently flag resmetirom plus gabapentin as a clinically significant interaction. This reflects the non-overlapping metabolic pathways described above. The absence of a flag does not mean the combination has been formally studied. It means that based on known pharmacology, a direct interaction is not predicted.

Clinicians should distinguish between "no interaction found" and "studied and found safe." The resmetirom label lists specific interactions with CYP3A4 modulators, OATP inhibitors, and BCRP substrates because those pathways were evaluated in dedicated PK studies [2]. Gabapentin was not included in the resmetirom clinical development DDI program because its pharmacology did not suggest a mechanistic basis for interaction.

Patient Counseling Points

Patients taking both medications should receive clear guidance on what to watch for and when to call their prescriber.

Tell patients to report new or worsening drowsiness, dizziness, or difficulty concentrating within the first 4 to 6 weeks of combination therapy. Advise against driving or operating heavy machinery until they know how the combination affects them. Remind patients that alcohol amplifies the sedative effects of gabapentin and may interact unpredictably with hepatic metabolism changes caused by resmetirom.

Patients should also understand that resmetirom may change their thyroid lab values. If they are seeing multiple providers (a hepatologist for MASH and a neurologist or pain specialist for the gabapentin indication), both clinicians need to know about the full medication list. Fragmented care is one of the most common sources of missed drug interactions in polypharmacy patients [10].

The Broader Interaction Field for Resmetirom

Gabapentin is one of many drugs that MASH patients may take alongside resmetirom. The more clinically significant interactions identified in the resmetirom label involve statins (particularly rosuvastatin, a BCRP substrate, which showed a 2-fold increase in AUC when co-administered with resmetirom) and strong CYP3A4 inhibitors like ketoconazole [2].

Patients on resmetirom plus a statin should have their statin dose evaluated at resmetirom initiation per the AASLD and ACC/AHA lipid guidelines [9]. For gabapentin specifically, the risk is lower, but the principle of active monitoring during any new combination therapy in a MASH population applies universally.

The FDA's postmarketing surveillance for resmetirom (ongoing through the REMS program and MedWatch) may generate additional real-world data on combination use patterns over the next 2 to 3 years. Until then, the pharmacologic analysis supports co-administration with standard monitoring rather than avoidance.

Patients starting resmetirom who are already stable on gabapentin should have a baseline assessment of sedation, renal function (serum creatinine and eGFR), and thyroid panel (TSH, free T4) documented before the first resmetirom dose, with repeat labs at 6 to 8 weeks [2].